Clinical Implications of Promoter Hypermethylation in RASSF1A and MGMT in Retinoblastoma  by Choy, Kwong Wai et al.
Clinical Implications of Promoter Hypermethylation
in RASSF1A and MGMT in Retinoblastoma1
Kwong Wai Choy*, Tom C. Lee y, Kin Fai Cheung*, Dorothy S. P. Fan*, Kwok Wai Lo z, Katherine L. Beaversony,
David H. Abramson y,§, Dennis S. C. Lam*, Christopher B. O. Yu* and Chi Pui Pang*
*Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China;
yNew York Presbyterian Hospital–Cornell Medical Center, New York, NY, USA; zDepartment of Anatomical
and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China; §Ophthalmic Oncology
Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Abstract
We investigated the epigenetic silencing and ge-
netic changes of the RAS-associated domain family
1A (RASSF1A) gene and the O6-methylguanine-DNA
methyltransferase (MGMT) gene in retinoblastoma.
We extracted DNA from microdissected tumor and
normal retina tissues of the same patient in 68 retino-
blastoma cases. Promoter methylation in RASSF1A
and MGMT was analyzed by methylation-specific
PCR, RASSF1A sequence alterations in all coding
exons by direct DNA sequencing, and RASSF1A
expression by RT-PCR. Cell cycle staging was ana-
lyzed by flow cytometry. We detected RASSF1A pro-
moter hypermethylation in 82% of retinoblastoma, in
tumor tissues only but not in adjacent normal retinal
tissue cells. There was no expression of RASSF1A
transcripts in all hypermethylated samples, but
RASSF1A transcripts were restored after 5-aza-2V-
deoxycytidine treatment with no changes in cell cycle
or apoptosis. No mutation in the RASSF1A sequence
was found. MGMT hypermethylation was present
in 15% of theretinoblastoma samples, and the ab-
sence of MGMT hypermethylation was associated
(P = .002) with retinoblastoma at advanced Reese-
Ellsworth tumor stage. Our results revealed a high
RASSF1A hypermethylation frequency in retinoblas-
toma. The correlation of MGMT inactivation by pro-
moter hypermethylation with lower-stage diseases
indicated that MGMT hypermethylation provides
useful prognostic information. Epigenetic mecha-
nism plays an important role in the progression
of retinoblastoma.
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Introduction
Alteration in genomic DNA methylation is an important
mechanism in the pathogenesis of human cancers and
is associated with the transcriptional repression of cancer-
associated genes [1]. Promoter hypermethylation and subse-
quent transcription silencing of tumor-suppressor genes such
as p16,RB1, BRCA1, and VHL promote tumorigenesis in many
types of cancers [2–5]. Identifying hypermethylation at the
CpG islands is an efficient alternative approach for detection
of disease-associated genes in ovarian cancer, renal carci-
noma, colorectal cancer, and breast cancer [2,5–10]. In retino-
blastoma, several tumor-suppressor genes and DNA repair
genes have been shown to be frequently inactivated due to
aberrant methylation at the 5V promoter regions including RB1
(14%) [11], RASSF1A (59%) [12], and MGMT (35%) [13].
These studies provide evidence that genes associated with
tumorigenesis acquire hypermethylation changes during
retinoblastoma development. The gene for the RAS associa-
tion domain family protein, RASSF1A, which is located at
3p21.3, encodes an Mr of 39,000 predicted peptide with a
Ras association domain. There is a predicted NH2 terminal
diacylglycerol binding domain. Rarely inactivated by mutations,
it has been suggested to be a tumor-suppressor gene on
the basis of its frequent inactivation through promoter hyper-
methylation in human cancers [14,15]. The epigenetic silencing
of the RASSF1A gene, brought forth by promoter hypermethy-
lation, commonly occurred in (40–72%) lung cancer [14,15],
(66.7%) nasopharyngeal carcinoma [16], (62%) primary mam-
mary carcinoma [17], (59%) retinoblastoma [12], and (45%)
adenocarcinoma of the uterine cervix [18]. RASSF1A is likely
involved in cell cycle control through the inhibition of cyclin D1
accumulation [19]. Recently, RASSF1A has been identified
as a microtubule binding protein that may play a role in the
control of microtubule stability [20], and regulates the stability
of mitotic cyclins and mitotic progression by inhibiting APC–
Cdc20 activity [21]. In vitro expression of RASSF1A in lung
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cancer cells resulted in suppression of colony formation and
anchorage-independent soft agar growth. It also suppressed
the malignant phenotype [14,15]. Thus, RASSF1A likely
serves as a tumor suppressor during cancer development
[14,15,22,23].
Loss of heterozygosity (LOH) on chromosome 3p is a
common and early event in the pathogenesis of lung
cancer, nasopharyngeal carcinoma, and other tumors.
However, LOH at 3p or 3p21.3 is not common in retino-
blastoma [23]. Loss of chromosome 3 has so far been
reported only in six retinoblastoma cases among a total of
101 cases reported in 16 studies [24–29]. Recently, a high
frequency (59%, 10/17) of promoter hypermethylation in
RASSF1A has been detected in retinoblastoma by Harada
et al. [12]. They suggested that epigenetic silencing in
RASSF1 might be one of the genetic targets involved in
the development of retinoblastoma. However, their number of
study subjects (n = 17) was small and there was a lack of
assessment on clinical correlations. It was unclear how
epigenetic silencing in RASSF1A correlated with the devel-
opment of retinoblastoma and whether epigenetic silencing
of RASSF1A could be an independent prognostic factor.
Meanwhile, in a previous study, we have shown that
promoter hypermethylation in MGMT in retinoblastoma
DNA was associated with impaired or absent MGMT ex-
pression at both mRNA and protein levels [13]. In this study,
we investigated the presence of 5V promoter methylation
and sequence changes at the coding regions of RASSF1A
on 40 bilateral and 28 unilateral retinoblastoma cases and
characterized their clinical significance. Also studied was
the relationship between promoter hypermethylation of
RASSF1A and MGMT, as well as whether demethylation
and reactivation of the RASSF1A gene by 5-aza-2V-deoxy-




Human retinoblastoma cell lines (WERI-Rb1, Y79) were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA) and cultured according to the recommended
conditions. Retinoblastoma tumor tissues were collected
from 68 retinoblastoma patients treated at the Hong Kong
Eye Hospital (n = 36) and the New York Presbyterian
Hospital (n = 32). Among the patients, 40 (59%) were
bilateral and 28 (41%) were unilateral. We obtained normal
retinal tissues from four unrelated donor cadaver eyes as
controls. Informed consent and institutional IRB have been
obtained for this study.
Reese-Ellsworth (RE) Classification for Retinoblastoma
Intraocular retinoblastoma was classified according to
the RE classification for retinoblastoma: group I [a) solitary
tumor, smaller than four disc diameters in size, at or behind
the equator; or b) multiple tumors, none larger than four disc
diameters in size, all at or behind the equator]; group II [a)
solitary tumor, 4 to 10 disc diameters in size, at or behind the
equator; or b) multiple tumors, 4 to 10 disc diameters in size,
behind the equator]; group III [a) any lesion anterior to the
equator; b) solitary tumor, larger than 10 disc diameters in
size, behind the equator]; group IV [a) multiple tumors, some
larger than 10 disc diameters in size; or b) any lesion
extending anterior to the ora serrata]; and group V [a)
massive tumors involving more than one half the retina; or
b) vitreous seeding].
Laser Capture Microdissection (LCM)
Weobtained over 90% tumor cells from the retinoblastoma
tissue samples by using the LCM system (PALM, Bernried,
Germany) to select cancerous tissue cells on slides accord-
ing to the manufacturer’s protocols. The procedure has been
described previously [13]. On average, about 20,000 tumor
cells from one specimen were yielded by LCM shots. DNA
was extracted by DNA extraction kit (Qiagen, Hilden, Ger-
many). Genomic DNA was also extracted from the corre-
sponding normal eye tissue cells.
Methylation-Specific Polymerase Chain Reaction (PCR)
For all retinoblastoma samples, normal control samples,
and the two retinoblastoma cell lines (WERI-Rb1 and Y79),
the 5V promoter DNA methylation status of RASSF1A and
MGMT was investigated by methylation-specific PCR (MSP)
assay as described previously [12,13]. Genomic DNA of the
microdissected specimens were modified by bisulfite treat-
ment, prior to MSP amplification [30]. Bisulfite-modified DNA
was also obtained from the retinoblastoma cell lines and
eight microdissected normal retinal tissues for MSP analysis.
Negative controls without DNA were included in each set of
assays. The methylation status was determined as a reflec-
tion of the presence of the methylated fraction of the exam-
ined genes. MSP analysis for each sample was repeated
three times. PCR products were analysed by 2% agarose gel
electrophoresis, stained with ethidium bromide, and visual-
ized under UV illumination.
DNA Sequencing
DNA was extracted from all 68 retinoblastoma samples
for direct sequencing to identify sequence alterations in all
RASSF1A coding exons and splicing regions using 10 PCR
amplicons [16]. The samples were sequenced by using the
dRhodamine Dye Terminator Cycle sequencing kit (Applied
Biosystems, Foster City, CA) on an automated ABI PRISM
377 Sequencer (Perkin Elmer).
Bisulfite Sequencing
DNA from the WERI-Rb1 and Y79 cell lines and four nor-
mal control retinal tissues were subjected to bisulfite se-
quencing to detect the methylation status of the promoter
region ofRASSF1A. Genomic DNAwere modified by bisulfite
treatment and purified using the CpGenome DNA Modifica-
tion Kit (Intergen, Purchase, NY) according to the manufac-
turer’s recommendations. Seminested PCR amplification
was performed on 100 ng of bisulfite-modified genomic
DNA as described by Dammann et al. [14]. The amplified
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fragments were subcloned. Ten clones of each sample were
selected for sequencing.
Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total mRNA was prepared from the tumor tissue sections
and normal adjacent retinal tissues obtained after microdis-
section of the retinoblastoma specimens by an RNeasy kit
(Qiagen). PCR was carried out with cDNA synthesised from
total mRNA using Superscript II reverse transcriptase (Gibco
BRL, Bethesda, MD) with 1 mM sense and antisense primers
as previously reported [16]. The RNA samples were also
amplified by the primers of the GAPDH gene as control.
5-AzaCdR Treatment and RT-PCR
To determine whether RASSF1A expression could be
restored by application of a demethylating agent, the
WERI-Rb1 and Y79 cell lines were subjected to 5-AzaCdR
treatment. Cells were grown in suspension culture and
incubated for 2 and 4 days with 3 or 5 mM 5-AzaCdR (Sigma
Chemical Co., St. Louis, MO). The medium and 5-AzaCdR
were replaced every 24 hours. Expression of the RASSF1A
transcript in the cell lines was examined by RT-PCR [16].
Cell Cycle Analysis
For flow cytometry analysis, cells (f5  106) were
harvested and washed with Hank’s balanced salt solution
(HBSS; Sigma-Aldrich, St. Louis, MO) and fixed in 70%
ethanol at 4jC for 2 hours. After passing through a 40-mm
cell strainer (Falcon; Becton Dickinson, Franklin Lakes,
NJ), cells were adjusted to 1  106 ml1 and stained with
propidium iodide (50 mg/ml). The cellular DNA content was
assessed by the System II software in a Coulter EPICS XL
MCL flow cytometer (Coulter Corporation, Miami, FL) and
analyzed with the Multicycle software (Phoenix Flow Sys-
tems, San Diego, CA).
Statistical Analysis
Fisher’s exact test or chi-square analysis was conducted
to estimate the relationships between hypermethylation and
the pathologic and clinical features of retinoblastoma.
Results
Methylation Status of the RASSF1A Promoter in
Retinoblastoma Samples
Of the 68 retinoblastoma carcinoma samples, 56 (82%)
showed hypermethylation at the CpG sites of the RASSF1A
promoter (Figure 1A). The retinoblastoma cell lines WERI-
Rb1 and Y79 were completely methylated (Figure 2A).
No RASSF1A promoter hypermethylation was detected
among the four normal control retinal specimens and the
microdissected normal retinal tissue sections adjacent to
the tumor tissues of the retinoblastoma specimens. Direct
sequencing further confirmed the 16 CpG sites of the
RASSF1A promoter from each of the two retinoblastoma
cell lines to be extensively methylated. There was no CpG
island methylation among the four normal retina tissues
examined (Figure 1B). These findings suggest that promoter
hypermethylation of the RASSF1A gene is a common epi-
genetic event in human retinoblastoma cells.
Figure 1.Methylation analysis of RASSF1A in retinoblastoma. (A) Representative MSP results of RASSF1A for retinoblastoma cancers. The PCR products in lane
U showed the presence of unmethylated templates, whereas, in lane M, they indicated the presence of methylated templates. In vitro SssI methyltransferease-
treated (positive) and untreated (WBC) DNA from normal lymphocytes were used as positive control for hypermethylation and unmethylation, respectively. (B)
Summary of 5-methylcytosine levels of the RASSF1A promoter detected by bisulfite sequencing. Two cell lines (WERI-Rb1 and Y79) and four normal and
nonmalignant retina tissues were examined. N1 and N2 are representative samples from normal retina.
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Mutation Screening of the RASSF1A Gene
Direct DNA sequencing after PCR of the RASSF1A
coding exons and splicing regions confirmed the presence
of polymorphisms at codons 53 (CGC to CGT), 56 (CCC to
CCT), and 57 (GCG to GCA) in our study samples [16]. No
somatic RASSF1A mutation has been detected in any of the
68 retinoblastoma tumor samples.
Expression of RASSF1A in Retinoblastoma Cell
Lines and Tissues
The WERI-Rb1 and Y79 cell lines and tumor specimens
with RASSF1A promoter hypermethylation did not express
theRASSF1A transcript (Figure 2B). However, expression of
RASSF1A mRNA was detected in all four control normal re-
tinal tissue samples and in all unmethylated retinoblastoma
tumors. Restoration of the gene expression was observed
in the retinoblastoma cell lines WERI-Rb1 and Y79 after
2 days of treatment with 5 mM 5-AzaCdR (Figure 2B). Fur-
thermore, demethylation of the promoter region was de-
tected (Figure 2A). These results confirmed that loss of
expression in the retinoblastoma cell lines was associated
with promoter hypermethylation (Figure 2A). Flow cytometry
examination of the cells after partial reactivation of
RASSF1A by 5-AzaCdR treatment showed that WERI-Rb1
had a slight (less than 7 ± 3%) increase in G2/M phase cells
on day 4 after treatment. No change in cell cycle was ob-
served for Y79 (Figure 2C). In both cells, no significant in-
crease of apoptosis was detected.
Relationship between RASSF1A and MGMT Methylation
Status in Retinoblastoma
Although promoter hypermethylation was detected in 56
(82%) of 68 retinoblastoma samples for RASSF1A, hyper-
methylation of the MGMT promoter was detected in 10 of
68 retinoblastoma samples (15%). There was no MGMT
hypermethylation detected in the retinoblastoma cell lines
WERI-Rb1 and Y79. There were no significant difference in
the ages at presentation, family history, sex, tumor staging,
or laterality between RASSF1A-methylated and unmethyl-
ated cases. Among the 56 retinoblastoma specimens with
promoter hypermethylation at RASSF1A, nine of them also
had MGMT hypermethylation. However, when the frequen-
cies of MGMT hypermethylation in retinoblastoma with
and without RASSF1A hypermethylation were compared
(9/56 vs 1/12), they were statistically insignificant. Clini-
cal information on tumor staging by RE classification was
available for 47 retinoblastoma tumors. Patient character-
istics were summarized in Table 1. Most of them were
at RE stage V (74%; 35/47) and RE stage IV (17%; 8/47);
only a few were at stage III (4%; 2/47) and stage II (3%;
2/47). Due to the small number of retinoblastoma cases
at individual RE stages II and III, we grouped them together
and compared with retinoblastoma tumors at RE stages
IV and V. MGMT or RASSF1A hypermethylation was found
in all tumor stages (RE II–V). MGMT hypermethylation
was frequently detected in RE stages II to III (50%; 2/2)
or stage IV (50%; 6/12), but significantly less among 6%
(2/35) RE stage V tumors (P = .002; Fisher’s exact test).
Meanwhile, RASSF1A hypermethylation was commonly
detected (63–100%) among tumors at all different RE
stages (Table 1).
Discussion
In this study, we detected promoter hypermethylation of
RASSF1A in 56 of 68 (82%) human retinoblastoma tumors.
The frequency is higher than the 59% reported in a
previous study, which involved 17 retinoblastoma samples
and provided no information on RASSF1A expression [12].
We showed for the first time that there was a complete
concordance between promoter hypermethylation and ex-
pression of RASSF1A in retinoblastoma cells. Our finding
showed that RASSF1A was not hypermethylated in normal
Figure 2. (A) Methylation analysis of RASSF1A in RB cell lines showing
demethylation by 5-AzaCdR resumed the unmethylated sequence (U). (B)
RT-PCR analysis of RASSF1A expression in retinoblastoma. Cell lines
(WERI-Rb1 and Y79) expressing RASSF1A transcripts after 2 days
treatment with 5 M 5-AzaCdR. Examples of completely methylated
retinoblastoma tumors (Arb22 and Yu44) showing the absence of RASSF1A
mRNA expression. Presence of RASSF1A transcript in unmethylaed
retinoblastoma (Yu54). HeLa cells were used as positive control. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), housekeeping gene, was
used as a control for RNA integrity. (C). FACS cell cycle profiles of RB cell
lines treated with 5 M 5-AzaCdR for 4 days. The x-axis measures the DNA
content of the cell (FL2A). The y-axis represents the number of cell counts
(events). A slight increase of G2/M-phase fraction was observed in WERI-
Rb1. However, there was no significant difference in the G2/M fraction
between the two cell lines after treatment.
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and nonmalignant retinal tissues adjacent to the tumor
tissues in retinoblastoma specimens, clearly indicating that
promoter hypermethylation of RASSF1A occurs specifically
in cancer. Our results thus implicated that alteration in
activity of the RAS signal transduction pathways
(RASSF1A) may play an important role during the patho-
genesis of retinoblastoma. There is mounting evidence that
RASSF1A functions as a tumor-suppressor gene. Trans-
fection and expression of RASSF1A in lung and renal
carcinoma cells have been shown to suppress colony
formation, anchorage-independent soft agar growth, and
nude mouse tumorigenicity [14,20,22,23]. RASSF1A is
frequently inactivated by hypermethylation in a variety of
tumors, including those in which 3p21 allele loss is com-
mon (lung, breast, and nasopharyngeal carcinomas) or
rare (papillary renal cell carcinoma) [14–16,31]. Its occur-
rence is different in specific types of tumors. In uterine
cervix cancer, it occurred at a high frequency in adeno-
carcinoma, but was not found in squamous cell carcinoma
[18]. Alternated DNA methylation at the CpG promoter
region could be a potentially promising molecular marker
for making early cancer diagnosis, predicting cancer risk,
and monitoring prognosis [32]. Methylated RASSF1A was
associated with impaired patient survival and poor prog-
nosis in non small cell lung cancer [15]. However, we
found no such association in retinoblastoma. The tumor-
suppressive properties of RASSF1A may therefore be
variable in different cancer types.
Previously, Shivakumar et al. [19] have demonstrated
that RASSF1A induced G0/G1 cell cycle arrest in H1299
lung carcinoma cells by decreasing cyclin D1 accumulation.
In this study, we found that both WERI-Rb1 and Y79 reti-
noblastoma cell lines carried a completely methylated
RASSF1A promoter and did not express RASSF1A. But
theRASSF1A gene was reactivated and was able to express
RASSF1A transcript after treatment with 5-AzadCdR, which
inhibited DNA methylation (Figure 2, A and B). No significant
alterations in cell cycle or apoptosis that were associated
with the reactivation of RASSF1A were found. Only a slight
increase in the G2/M-phase fraction was observed in the
WERI-Rb1 cell line, in which RASSF1A was reactivated after
4 days of 5-AzadCdR treatment (Figure 2C). This suggested
that the G2/M cell phase changes identified in theWERI-Rb1
cell line might not be a specific tumor-suppressing effect
caused by RASSF1A reactivation. However, the lack of
effects on cell growth or cell cycle may be due to the limited
amount of RASSF1A transcript that was reexpressed. Our
results indicated that 5-AzadCdR could not completely re-
store RASSF1A because there was still presence of meth-
ylated alleles (Figure 2A). To understand the functional role
of RASSF1A in retinoblastoma development, it is important
to study the effects of the exogenous expression of
RASSF1A on retinoblastoma tumor cell phenotype. Whether
loss of RASSF1A may affect spindle function and hence
mitotic aberrations in retinoblastoma should be investigated.
MGMT promoter hypermethylation was associated with a
significant increase in overall survival in diffuse large B-cell
lymphomas [33] and gliomas [34]. The pathogenesis of
retinoblastoma is known to involve inactivation of both
copies of the RB1 gene and other genetic or epigenetic
alterations in independent molecular pathways. In this
study, the presence of MGMT methylation was significantly
less among RE stage V tumors (Table 1). Consistent with
our previous report, which indicated that MGMT hyper-
methylation might be related to poor differentiation [13], in
this study, hypermethylation of MGMT promoter was more
frequently identified among undifferentiated cases (60%)
than differentiated tumor samples (40%). When MGMT
methylation status was correlated with clinical staging, there
was greater frequency of hypermethylation in lower-stage
diseases (Table 1). However, the relatively low frequency of
cases (10 of 68, 15%) with MGMT hypermethylation pre-
cluded us from making statistical inference, although it is
known to be significantly associated with longer progression-
free survival time in diffused large B-cell lymphomas [33].
The levels of MGMT activities and protein levels vary widely
Table 1. Clinicopathologic Characteristics of Retinoblastoma Tumor as a Function of RASSF1A and MGMT Promoter Methylation Status.
RASSF1A Gene Status P MGMT Gene Status P
Methylated Unmethylated Methylated Unmethylated
Laterality
Bilateral 32 8 .543 6 34 .935
Unilateral 24 4 4 24
Histology
Differentiated 21 5 .297 4 32 .730
Undifferentiated 29 6 6 22
N/A 6 1 0 4
RE classification
II to III 4 0 .180 2 2 .002*
IV 5 3 4 4
V 31 4 2 33
N/A 16 5 2 19
Optic nerve invasion 8 1 .567 1 8 .826
MGMT hypermethylation is significantly less among 6% (2/35) RE stage V tumors ( P = .002; Fisher’s exact test) compared to RE stage II, III, or IV.
N/A = not available.
*All P values <.05 are considered statistically significant.
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in tumors, are abundant in B-cell lymphomas, and are unde-
tectable in gliomas [33,34]. MGMT deficiency increased the
sensitivity of brain tumor to alkylating agents [34]. In retino-
blastoma, alkylating agents such as the platinum compounds
carboplatin or cisplatin have been commonly used for treat-
ment [34,35]. Therefore, MGMT inactivation may render the
retinoblastoma cells more prone to genotoxic effects of
alkylating agents, as has been proposed in glioma [34].
Besides, the presence of MGMT may confer increased
resistance on the elimination of transformed retina cells to
methylating and chloroethylating agents. Effects of MGMT
hypermethylation on response to chemotherapy should be
investigated in retinoblastoma.
In contrast, we found the presence of RASSF1A pro-
moter hypermethylation in a very high proportion (82%) of
retinoblastoma cases regardless of age at presentation,
sex, laterality, histology, family history, tumor staging, or
optic nerve involvement (Table 1). Our data showed that
loss of RASSF1A expression by promoter hypermethylation
is the most common epigenetic change that is known in
retinoblastoma. Such epigenetic silencing was not detected
among normal or nonmalignant retina tissues, further sug-
gesting the contribution of inactivation of RASSF1A to the
progression of retinoblastoma.
In conclusion, the large proportion of retinoblastoma cases
with RASSF1A and MGMT promoter hypermethylation as
well as the absence of mutations in theRASSIFIA sequences
that cause retinoblastoma clearly show the important role of
epigenetic mechanism on retinoblastoma progression.
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